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Cystic fibrosis (CF)-related lung disease is characterized by a broad spectrum of pathologic changes. Most of these changes relate to
progressive bronchiectasis and airway destruction due to recurrent infections. Other airway pathologies include but are not limited to nasal
polyposis, bronchial hyperactivity, pneumothorax and allergic bronchopulmonary aspergillosis (ABPA). Constrictive obliterative
bronchiolitis (COB) in CF is usually seen in post-transplant settings including lung and heart–lung transplants. We report a 13-year-old
boy with CF and intractable deterioration in lung function that was ultimately diagnosed as COB.
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Constrictive obliterative bronchiolitis (COB) is charac-
terized by a partial or complete occlusion of terminal and
respiratory bronchioles by inflammation and fibrous tissue.
It is a rare disease that produces a progressive and irre-
versible obstructive lung disease following exposure to toxic
fumes, infections, drugs and autoimmune diseases. In cystic
fibrosis (CF), most cases of COB are seen in the years
following lung transplantation with the incidence ranging
from 34% to 50% in one report [1]. We report a 13-year old
male with CF and gradual deterioration in lung function who
was ultimately diagnosed with COB. This sub-type of
bronchiolitis obliterans diagnosed by transbronchial biopsy
is discussed with emphasis on the clinical presentation,
pathology and radiographic presentation as well as manage-
ment options.⁎ Corresponding author. Division of Pulmonary Medicine, Cincinnati
Children's Hospital Medical Center, ML 2021, 3333 Burnet Avenue,
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We present a 13-year-old male with CF. He was diagnosed
at 3 months of age, when he presented with recurrent upper
respiratory tract infection. A sweat test confirmed the
diagnosis and he has a homozygous Delta F508 genotype.
His first hospitalization for bronchopneumonia was at 4 years
of age, and subsequently, he had pulmonary exacerbation
requiring hospital admission every other year until age ten.
His sputum cultures were positive for methicillin resistant
Staphylococcus aureus (MRSA) and intermittently, multi-
drug resistant Pseudomonas aeruginosa. His lung function
remained at a baseline of 103% predicted. At 10 years of age,
his FEV1 began to gradually decline to 77% predicted over
4 months. Multiple courses of intravenous antibiotics did not
reverse this trend. At this time, work up with high resolution
computed tomography scan (HRCT) revealed air-trapping.
Severe gastroesophageal reflux disease (GERD) was diag-
nosed by pH probe, allergic bronchopulmonary aspergillosis
(ABPA) was suspected on the basis of an IgE level of
1325 kU/L and a positive Aspergillus skin test. However, his
bronchoalveolar lavage (BAL) culture for Aspergillus and
serum specific IgE for Aspergillus fumigatus were negative.ed by Elsevier B.V. All rights reserved.
Fig. 1. Rapid decline in FEV1 at more than 5–10% per year.
Fig. 3. Tissue from lung biopsy showing patent alveoli and obliterated
bronchioles and remnant elastic fibers (arrow) on VVG staining.
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ultimately, nissen fundoplication. He received empirical
treatment with prednisone for ABPA. However, his lung
function continued to decline to an FEV1 of 30% of predicted
over the next 3 years (Fig. 1) His flow-volume curve was
obstructive in shape with no bronchodilator response and his
residual volume was 209% predicted.
He was hospitalized for an acute exacerbation and given
the presence of his persistently decreased lung function,
additional testing for his frequent pulmonary exacerbation
was again pursued. HRCT showed interval increase in
expiratory air trapping, mosaic attenuation (Fig. 2) and
minimal parenchymal changes that did not appear to be
consistent with his markedly diminished lung function. His
antinuclear antibody, C3, C4, Rheumatoid factor, Adenoviral
PCR and mycoplasma titers were negative. His BAL culture
was positive for Geotrichum capitatum and A. fumigatus.Fig. 2. HRCTwith mosaic attenuation on expiratory image showing areas of
higher attenuation in areas of healthy lungs compared to areas of low
attenuation (arrows) in areas with air trapping.At day 16, he underwent a thoracoscopic lung biopsy.
Lung biopsy confirmed constrictive bronchiolitis with
minimal inflammation (Fig. 3). G. capitatum was treated
with voriconazole and oral prednisone for ABPA; however,
his FEV1 remained at 30% predicted. He is now listed for
lung transplant.
3. Discussion
The volume of literature on bronchiolitis obliterans has
increased since its description by Lange in 1901. It is essen-
tially a pathologic diagnosis but the term has been used to
describe a clinical syndrome- Bronchiolitis obliterans
syndrome (BOS) and two distinct pathologic patterns,
COB and cryptogenic organizing pneumonia (COP). COB
is a histological lesion defined by alteration in the walls of
the bronchioles ranging from inflammation to fibrosis and
ultimately, to complete obliteration of the lumen [2]. The
distal lung parenchyma is not involved. COP is characterized
histologically by intraluminal exudates in the respiratory
bronchioles and alveolar spaces as well as in the more distal
parenchyma. BOS is a clinical term describing the
progressive airflow limitation caused by small airway
obstruction which frequently complicates lung transplanta-
tion. It is defined by changes on spirometry but the
corresponding histopathologic pattern is constrictive oblit-
erative bronchiolitis [3], such as seen in our patient (Fig. 3).
In nontransplant cases, the causes range from idiopathic to
infections, toxic fumes, drugs, and connective tissue disease.
COB in cystic fibrosis is usually suspected as a cause of
respiratory distress in post-transplant settings, this is why
initial efforts were concentrated on treating infections,
ABPA, GERD, none of which reversed his lung function.
To the best of our knowledge, this is the first reported case of
histologically proven COB in a pre-transplant CF patient.
The clinical presentation of COB includes flu-like illness,
non-productive cough and dyspnea. Wheezing is usually
absent but early inspiratory crackles are present on exam-
ination. Chest X-ray shows hyperinflation ormay be normal in
94 P.O. Sobande et al. / Journal of Cystic Fibrosis 7 (2008) 92–9440% of cases. HRCT will show areas of low attenuation,
mosaic perfusion and expiratory air trapping. Lung function
test will show fixed obstructive pattern with decrease FEV1,
FEV1/FVC and increase in RV suggesting air-trapping. The
diffusing capacity is highly variable from increase to normal to
significant decrease. The gold standard of diagnosis for COB
is lung biopsy but the patchy distribution of the lesion
decreases its sensitivity. The literature is replete with studies on
pathogenesis, presentation and management of COB in post-
transplant settings but studies on therapy for nontransplant-
related CBO are small and inadequate with inconsistent
response to steroid.Azithromycin has been reported to halt and
reverses COB in post transplant settings in a case series with
small sample size, in which all the patients were maintained on
immunosuppressive therapy. Lung transplantation with its
potential complications is another option. While there is no
evidence in the literature implicating G. capitatum as a cause
of COB, clinicians should note that secondary recurrent
opportunistic fungal and bacterial infections are predominant
once COB is established. Such infections can bemistaken for a
primary process such as pulmonary exacerbation in CF. Ourcase emphasizes the need for lung biopsy in patients with
intractable deterioration in lung function.
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